Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Orchestra BioMed Holdings Inc. (OBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: OBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.57
1 Year Target Price $13.57
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.24% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 106.51M USD | Price to earnings Ratio - | 1Y Target Price 13.57 |
Price to earnings Ratio - | 1Y Target Price 13.57 | ||
Volume (30-day avg) 7 | Beta 0.63 | 52 Weeks Range 2.37 - 8.87 | Updated Date 06/30/2025 |
52 Weeks Range 2.37 - 8.87 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2179.84% |
Management Effectiveness
Return on Assets (TTM) -60.7% | Return on Equity (TTM) -179.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 73068783 | Price to Sales(TTM) 36.91 |
Enterprise Value 73068783 | Price to Sales(TTM) 36.91 | ||
Enterprise Value to Revenue 25.32 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 38312500 | Shares Floating 17204617 |
Shares Outstanding 38312500 | Shares Floating 17204617 | ||
Percent Insiders 21.78 | Percent Institutions 49.83 |
Analyst Ratings
Rating 3 | Target Price 13.57 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Orchestra BioMed Holdings Inc.
Company Overview
History and Background
Orchestra BioMed Holdings, Inc. was founded in 2021 through a merger of Propel Bio Management and Orchestra BioMed, Inc. It is focused on developing innovative cardiovascular therapies.
Core Business Areas
- BackBeat Cardiac Neuromodulation Therapy (CNT): Developing a potential therapy for hypertension using cardiac neuromodulation, designed to immediately and substantially lower blood pressure. Currently in clinical trials.
- Virtue Sirolimus-Eluting Balloon (SEB): Developing a drug-eluting balloon for the treatment of artery disease. This product is expected to lower the rate of restenosis as compared to other balloons. Currently in clinical trials.
Leadership and Structure
Ron Ozurovich is the Chief Executive Officer. The company operates with a focus on clinical development and regulatory approval of its core technologies.
Top Products and Market Share
Key Offerings
- BackBeat CNT: A neuromodulation therapy targeting hypertension. Market share is currently 0% as it is still in clinical development, but there is potential in the anti-hypertension market. Competitors include pharmaceutical companies producing hypertension medications, companies developing renal denervation devices (e.g., Medtronic, ReCor Medical).
- Virtue SEB: A sirolimus-eluting balloon for treating artery disease. Market share is currently 0% as it is still in clinical development, but it aims to compete in the drug-eluting balloon market. Competitors include Boston Scientific, Medtronic, Abbott, and other manufacturers of drug-eluting stents and balloons.
Market Dynamics
Industry Overview
The cardiovascular device market is a large and growing market, driven by an aging population and increasing prevalence of cardiovascular diseases. It is characterized by constant innovation and stringent regulatory requirements.
Positioning
Orchestra BioMed is positioning itself as an innovator in cardiovascular therapies, focusing on areas with unmet needs, such as hypertension and restenosis. Its competitive advantage lies in its unique technologies and potential to improve patient outcomes.
Total Addressable Market (TAM)
The total addressable market for hypertension treatment and artery disease is estimated to be in the billions of dollars. Orchestra BioMed aims to capture a significant portion of this TAM with its innovative therapies.
Upturn SWOT Analysis
Strengths
- Innovative technologies with potential for improved patient outcomes
- Experienced leadership team
- Strategic partnerships
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
- Dependence on financing for research and development
- Limited operating history
Opportunities
- Growing market for cardiovascular devices
- Increasing prevalence of hypertension and artery disease
- Potential for regulatory approval and market access
- Expansion into new markets and indications
Threats
- Competition from established players
- Regulatory hurdles and delays
- Unsuccessful clinical trial results
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MDT
- BSX
- ABT
Competitive Landscape
Orchestra BioMed faces significant competition from established players in the cardiovascular device market. Its success will depend on demonstrating superior clinical outcomes and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable due to the company's recent formation through a merger.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals of its core technologies. Analyst estimates anticipate revenue generation following commercialization of its products.
Recent Initiatives: Recent initiatives include advancing clinical trials for BackBeat CNT and Virtue SEB, and securing financing to support research and development.
Summary
Orchestra BioMed is a development-stage company with innovative cardiovascular technologies targeting significant unmet needs. Its success hinges on successful clinical trials and regulatory approvals. The company faces strong competition and relies on continued financing to support its R&D efforts, but the potential market opportunity is substantial if its technologies prove effective.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry reports
Disclaimers:
This analysis is based on available information and estimates, and should not be considered investment advice. The information provided is not guaranteed to be accurate or complete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Orchestra BioMed Holdings Inc.
Exchange NASDAQ | Headquaters New Hope, PA, United States | ||
IPO Launch date 2020-08-04 | Founder, Chairman of the Board of Directors & CEO Mr. David P. Hochman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://orchestrabiomed.com |
Full time employees 70 | Website https://orchestrabiomed.com | ||
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.